Welcome to LookChem.com Sign In|Join Free

CAS

  • or

207726-35-0

Post Buying Request

207726-35-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

207726-35-0 Usage

Uses

Ethyl 4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidine-1-carboxylate can be used in the preparation of [(chlorophenyl)(pyridinyl)methoxy]piperidinebutanoic acid (bepotastine) (CAT# B316095), which is a histamine H1 receptor antagonist.

Check Digit Verification of cas no

The CAS Registry Mumber 207726-35-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,7,7,2 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 207726-35:
(8*2)+(7*0)+(6*7)+(5*7)+(4*2)+(3*6)+(2*3)+(1*5)=130
130 % 10 = 0
So 207726-35-0 is a valid CAS Registry Number.
InChI:InChI=1/C20H23ClN2O3/c1-2-25-20(24)23-13-10-17(11-14-23)26-19(18-5-3-4-12-22-18)15-6-8-16(21)9-7-15/h3-9,12,17,19H,2,10-11,13-14H2,1H3

207726-35-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names 4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidine-1-carboxylic acid ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:207726-35-0 SDS

207726-35-0Relevant articles and documents

Total synthesis method of bestatin

-

Paragraph 0020; 0050; 0054-0055; 0066; 0070-0071, (2021/10/11)

The method comprises the following steps: (4 - chlorophenyl) (2 - pyridyl) - methanol as a starting raw material, and sequential addition reaction. Examples of the etherification reaction include a deprotection reaction, a chiral resolution, a condensation reaction, a hydrolysis reaction, and the like. The synthesis method has the advantages of cheap and easily available raw materials, no need of expensive chiral catalysts, simpler synthesis method, mild conditions, less side reactions and low cost.

Method for preparing bepotastine besilate key intermediate

-

Paragraph 0018, (2019/04/26)

The invention relates to a method for preparing a bepotastine besilate key intermediate, in particular to 4-[(4-chlorphenyl)(2-pyridyl)methoxyl]piperidine-1-formate prepared from alpha-(4-chlorphenyl)-2-pyridinemethanol and 4-halogenated piperidine-1-carb

A novel synthetic method for bepotastine, a histamine H1 receptor antagonist

Ha, Tae Hee,Suh, Kwee-Hyun,Lee, Gwan Sun

, p. 549 - 552 (2013/08/25)

An efficient and alternative synthesis of enantiomerically pure (+)-(S)-4-(4-((4-chlorophenyl)(pyrid-2-yl)methoxy]piperidin-1-yl)butanoic acid, bepotastine (1) is described. The key resolution of (R/S)-bepotastine l-menthyl ester (3) is achived via diastereomeric salt crystallization using N-benzyloxycarbonyl-L-aspartic acid (NCbzLAA) as the resolving agent to provide (S)-bepotastine l-menthyl ester (S)-3. Hydrolysis of (S)-bepotastine l-menthyl ester (S)-3 afforded the desired bepotastine (1) with good yields and enantiopurity (> 99%). Finally, bepotastine besilate (4) and bepotastine calcium (5) are achived by salt formation of bepotastine (1) with benzene sulfonic acid and calcium salt respectively. The reaction conditions were optimized to make suitable for commercial scale production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 207726-35-0